Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Springer full text link Springer Free PMC article
Full text links

Actions

Share

Comparative Study
.2014 Dec;16(4):686-96.
doi: 10.1007/s12017-014-8318-6.

Apolipoprotein E isoform-specific effects on lipoprotein receptor processing

Comparative Study

Apolipoprotein E isoform-specific effects on lipoprotein receptor processing

Corbin Bachmeier et al. Neuromolecular Med.2014 Dec.

Abstract

Recent findings indicate an isoform-specific role for apolipoprotein E (apoE) in the elimination of beta-amyloid (Aβ) from the brain. ApoE is closely associated with various lipoprotein receptors, which contribute to Aβ brain removal via metabolic clearance or transit across the blood–brain barrier (BBB). These receptors are subject to ectodomain shedding at the cell surface, which alters endocytic transport and mitigates Aβ elimination. To further understand the manner in which apoE influences Aβ brain clearance, these studies investigated the effect of apoE on lipoprotein receptor shedding. Consistent with prior reports, we observed an increased shedding of the low-density lipoprotein receptor (LDLR) and the LDLR-related protein 1 (LRP1) following Aβ exposure in human brain endothelial cells. When Aβ was co-treated with each apoE isoform, there was a reduction in Aβ-induced shedding with apoE2 and apoE3, while lipoprotein receptor shedding in the presence of apoE4 remained increased. Likewise, intracranial administration of Aβ to apoE-targeted replacement mice (expressing the human apoE isoforms) resulted in an isoform-dependent effect on lipoprotein receptor shedding in the brain (apoE4 > apoE3 > apoE2). Moreover, these results show a strong inverse correlation with our prior work in apoE transgenic mice in which apoE4 animals showed reduced Aβ clearance across the BBB compared to apoE3 animals. Based on these results, apoE4 appears less efficient than other apoE isoforms in regulating lipoprotein receptor shedding, which may explain the differential effects of these isoforms in removing Aβ from the brain.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Appearance of extracellular soluble (A) LRP1 or (B) LDLR in human brain endothelial cells (HBMEC) upon treatment with Aβ (1–42). HBMEC were exposed to various concentrations (0.1, 0.2, 1, 2, and 10 µM) of human Aβ(1–42) for 48 hours at 37°C. Following the treatment period, the extracellular media was collected and analyzed for LRP1 or LDLR content by ELISA. Values represent mean ± SEM (n = 3) and are expressed as ng of LRP1 or LDLR per ml of media. *P< 0.05 compared to control as determined by ANOVA and Bonferroni post-hoc test.
Fig. 1
Fig. 1
Appearance of extracellular soluble (A) LRP1 or (B) LDLR in human brain endothelial cells (HBMEC) upon treatment with Aβ (1–42). HBMEC were exposed to various concentrations (0.1, 0.2, 1, 2, and 10 µM) of human Aβ(1–42) for 48 hours at 37°C. Following the treatment period, the extracellular media was collected and analyzed for LRP1 or LDLR content by ELISA. Values represent mean ± SEM (n = 3) and are expressed as ng of LRP1 or LDLR per ml of media. *P< 0.05 compared to control as determined by ANOVA and Bonferroni post-hoc test.
Fig. 2
Fig. 2
Appearance of extracellular soluble (A) LRP1 or (B) LDLR in human brain endothelial cells (HBMEC) in the presence of Aβ(1–42), apoE isoforms, or combinations thereof. HBMEC were treated with human Aβ(1–42) (2µM) and/or each apoE isoform (25ng/ml) for 48 hours at 37°C. Following the treatment period, the extracellular media was collected and analyzed for LRP1 or LDLR content by ELISA. Values represent mean ± SEM (n = 3) and are expressed as ng of LRP1 or LDLR per ml of media. *P< 0.05 compared to control. *P< 0.05 comparing apoE4 in the presence of Aβ versus apoE2 or apoE3 in the presence of Aβ, as indicated on the graph. Statistics determined by ANOVA and Bonferroni post-hoc test.
Fig. 2
Fig. 2
Appearance of extracellular soluble (A) LRP1 or (B) LDLR in human brain endothelial cells (HBMEC) in the presence of Aβ(1–42), apoE isoforms, or combinations thereof. HBMEC were treated with human Aβ(1–42) (2µM) and/or each apoE isoform (25ng/ml) for 48 hours at 37°C. Following the treatment period, the extracellular media was collected and analyzed for LRP1 or LDLR content by ELISA. Values represent mean ± SEM (n = 3) and are expressed as ng of LRP1 or LDLR per ml of media. *P< 0.05 compared to control. *P< 0.05 comparing apoE4 in the presence of Aβ versus apoE2 or apoE3 in the presence of Aβ, as indicated on the graph. Statistics determined by ANOVA and Bonferroni post-hoc test.
Fig. 3
Fig. 3
Expression of (A) LRP1 and (B) LDLR in cerebrovasculature isolated from apoE transgenic mice. Human Aβ(1–42) or vehicle was intracranially administered to male mice (4–6 months old). Ten minutes after the intracerebral injection, the brains were collected and various brain fractions were isolated. LRP1 or LDLR levels in the cerebrovasculature were determined using an ELISA and normalized to total protein content using the BCA protein assay. Values represent mean ± SEM (n = 6 animals) and are expressed as ng of LRP1 or LDLR per mg protein. No comparisons reached statistical significance as determined by ANOVA and Bonferroni post-hoc test.
Fig. 3
Fig. 3
Expression of (A) LRP1 and (B) LDLR in cerebrovasculature isolated from apoE transgenic mice. Human Aβ(1–42) or vehicle was intracranially administered to male mice (4–6 months old). Ten minutes after the intracerebral injection, the brains were collected and various brain fractions were isolated. LRP1 or LDLR levels in the cerebrovasculature were determined using an ELISA and normalized to total protein content using the BCA protein assay. Values represent mean ± SEM (n = 6 animals) and are expressed as ng of LRP1 or LDLR per mg protein. No comparisons reached statistical significance as determined by ANOVA and Bonferroni post-hoc test.
Fig. 4
Fig. 4
Levels of (A) LRP1 and (B) LDLR in the soluble brain fraction of apoE transgenic mice. Human Aβ(1–42) or vehicle was intracranially administered to male mice (4–6 months old). Ten minutes after the intracerebral injection, the brains were collected and various brain fractions were isolated. LRP1 or LDLR levels in the soluble brain fraction were determined using an ELISA. Values represent mean ± SEM (n = 6 animals) and are expressed as ng of LRP1 or LDLR per ml of soluble brain material. *P< 0.05 comparing apoE4 to apoE2 or apoE3 for the respective vehicle and Aβ(1–42) groups as determined by ANOVA and Bonferroni post-hoc test.
Fig. 4
Fig. 4
Levels of (A) LRP1 and (B) LDLR in the soluble brain fraction of apoE transgenic mice. Human Aβ(1–42) or vehicle was intracranially administered to male mice (4–6 months old). Ten minutes after the intracerebral injection, the brains were collected and various brain fractions were isolated. LRP1 or LDLR levels in the soluble brain fraction were determined using an ELISA. Values represent mean ± SEM (n = 6 animals) and are expressed as ng of LRP1 or LDLR per ml of soluble brain material. *P< 0.05 comparing apoE4 to apoE2 or apoE3 for the respective vehicle and Aβ(1–42) groups as determined by ANOVA and Bonferroni post-hoc test.
Fig. 5
Fig. 5
Western blot analysis of brain fractions isolated from wild-type mice. Brain fractions from wild-type male mice (4–6 months old) were examined for the presence of LRP-85 (marker for the membrane-bound subunit of LRP1), laminin (brain blood vessel marker), synaptophysin (neuronal marker) and the housekeeping protein actin. Samples were collected from the brain fractions of three naïve (i.e., no intracerebral injection) wild-type mice and loaded into separate lanes of the gel.
Fig. 6
Fig. 6
Correlation between brain lipoprotein receptor shedding and Aβ clearance across the BBB in apoE transgenic mice. LRP1 and LDLR levels in the soluble fraction of the brain were plotted versus the appearance of Aβ in the plasma (i.e., Aβ BBB clearance) following intracerebral Aβ administration (LRP1, R2 = 0.94; LDLR, R2 = 0.96). The Aβ BBB clearance data was derived from our previously published work (Bachmeier et al. 2013). Values represent the mean of 6 animals for each genotype. p < 0.05 for both LRP1 and LDLR as determined by Pearson correlation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging. 2012;33(3):e1–e14. - PMC - PubMed
    1. Arelin K, Kinoshita A, Whelan CM, Irizarry MC, Rebeck GW, Strickland DK, et al. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Res Mol Brain Res. 2002;104(1):38–46. - PubMed
    1. Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol. 2009;47(4):289–299. - PubMed
    1. Bachmeier C, Mullan M, Paris D. Characterization and use of human brain microvascular endothelial cells to examine beta-amyloid exchange in the blood-brain barrier. Cytotechnology. 2010;62(6):519–529. - PMC - PubMed
    1. Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F. A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neurodegener Dis. 2013;11(1):13–21. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp